The company's share price has risen sharply in response.
Kamada Ltd. (TASE: KMDA) has successfully completed Phase II trials of its flagship product. In response to the company's announcement, its share price rose some 4%.
The product, AAT, is for the treatment of the respiratory disease bronchiectasis. The company said that the results indicated an excellent safety profile for the drug, and yielded important clinical information about other chronic respiratory conditions, including cystic fibrosis.
The US Food and Drug Administration has granted AAT for treating bronchiectasis orphan drug status.
Published by Globes [online], Israel business news - www.globes.co.il - on June 8, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009